Association for Accessible Medicines (Formerly - Generic Pharmaceutical Assn)
Association representing the interests of the generic pharmaceutical industry.
Based in DC
AI Overview
With $1.3M in lobbying spend across 22 quarterly filings, Association for Accessible Medicines (Formerly - Generic Pharmaceutical Assn) is a significant lobbying presence. Their lobbying covers 6 issue areas. Active from 2018 to 2023.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $240K |
| 2019 | $300K |
| 2020 | $240K |
| 2021 | $240K |
| 2022 | $240K |
| 2023 | $20K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Copyright/Patent, Medicare/Medicaid, Trade, Health Issues, Pharmacy and 1 more
- •Issues related to abuses of the patent system, extensions of drug exclusivity, pay for delay, and the inter parties review (IPR) process.
- •Provisions affecting the Medicaid rebate program included in the Bipartisan Budget Act of 2015. Proposals related to Medicare treatment of biosimilar pass through payments and eliminating the exclusi
- •Issues related to global competitiveness of the generic and biosimilar industry.
- •General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars, including
- •Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 2212 and S.974, the CREATES Act of 2017, and H. R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.